ReWalk Robotics Ltd, a manufacturer of robotic medical technology for people with lower extremity disabilities, announces it will begin submitting Medicare cases following CMS’s September 26, 2022, announcement affirming that the Medicare Administrative Contractors (MACs) have discretion to cover and reimburse for the ReWalk exoskeleton. ReWalk Robotics is actively engaged with CMS in its commitment to evaluate complex advanced technologies like exoskeletons.

“We are pleased CMS has provided a pathway to submit cases while they continue to deliberate on the benefit category designation,” said Larry Jasinski, Chief Executive Officer (CEO) of ReWalk. “In light of this announcement, ReWalk will begin submitting cases for Medicare beneficiaries with spinal cord injury (SCI) to the MACs. All patients with spinal cord injury deserve access to revolutionary technologies that significantly improve their health. We will continue to advocate for Medicare to provide these innovative life-changing devices to beneficiaries with SCI.”

This is the latest step in ReWalk’s efforts to expand access to the Company’s exoskeletons for Medicare beneficiaries with SCI. Studies have shown that the ability to ambulate with an exoskeleton has a profound and beneficial impact on health outcomes for individuals with SCI, including through improved mental health, increased gastrointestinal (GI) function and other improvements on the health consequences of a SCI. ReWalk has prioritized working with payers like Medicare to ensure coverage of and access to exoskeleton technologies for individuals who are paralyzed or disabled due to SCI, so they are able to once again experience the health and well-being benefits of functional ambulation.

[Source(s): ReWalk Robotics Ltd, GlobeNewswire]

Related Content:
ReWalk Robotics is Now Certified as a Medicare Provider